The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
Zasocitinib outperformed Sotyktu 2.5x on complete psoriasis clearance, validating Takeda's $4B drug-discovery acquisition. The result signals market shift toward oral therapies, expected to triple in a decade, reshaping competitive strategy and budget allocation in biopharma.
An article from
Dive Brief
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
Published June 11, 2026
Takeda's experimental drug zasocitinib helped eliminate itchy lesions in people with psoriasis in a clinical trial.
Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Takeda Pharmaceutical Co (NYSE:
Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an…
Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3 study, showing higher skin clearance…
Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers…
Two months after UCB revealed the success of Bimzelx in a head-to-head trial aga | Two months after UCB revealed the success of…
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth…
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology…
